Efficacy And Safety of Neoadjuvant Therapy of Pembrolizumab combined with Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer: An Open-label Single-arm Phase II Study
Efficacy And Safety of Neoadjuvant Therapy of Pembrolizumab combined with Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer: An Open-label Single-arm Phase II Study
(2)治験責任医師等に関する事項
坪井 正博
Tsuboi Masahiro
国立研究開発法人国立がん研究センター東病院
National Cancer Center Hospital East
呼吸器外科
Division of Thoracic Surgery
千葉県柏市柏の葉6-5-1
6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577
04-7133-1111
energy@east.ncc.go.jp
宮本 博
Miyamoto Hiroshi
株式会社ファイブリングス
FiveRings CO.,LTD.
プランニングチーム
Planning Team
大阪府大阪市北区東天満1-1-19 アーバンエース東天満ビル
1-1-19 Kitakuhigashitenma, Osaka-shi, Osaka 530-0044, Japan
06-6358-7110
studycenter@fiverings.co.jp
2019年06月26日
(3)その他の試験等に従事する者に関する事項
株式会社ファイブリングス
株式会社ファイブリングス
株式会社アクセライズ
株式会社CLINICAL STUDY SUPPORT
株式会社ファイブリングス
(4)多施設共同試験等における治験責任医師等に関する事項など
あり
国立がん研究センター東病院、東京医科大学病院
National Cancer Center Hospital East,Tokyo Medical University Hospital
A phase 2 trial to demonstrate the antitumor activity and safety of neoadjuvant pembrolizumab plus ramucirumab followed by surgery in patients with PD-L1 positive stage 1B-3A non-small cell lung cancer
2
2
2019年09月30日
2019年01月01日
2024年06月30日
24
介入研究
Interventional
非盲検単アーム第II相臨床試験
Open-label Single-arm Phase 2 Study
治療
treatment purpose
/
日本
Japan
/
1. 同意取得時年齢が20歳以上である。
2. 組織学的に確認された未治療の非小細胞肺癌で、かつ本試験登録前に採取された腫瘍検体について、免疫組織化学染色で測定したPD-L1発現が1%以上を有している。
※本試験では免疫組織化学染色抗体は22C3抗体を使用する。
3. 臨床病期IB期、II期もしくはIIIA期と診断されている。(UICC TNM分類第8版)
※縦隔リンパ節転移陽性(N2)の診断は、縦隔鏡検査もしくは超音波気管支鏡(EBUS)ガイド下の生検、あるいは吸引細胞診等で病理学的に確認されていることを必須とする。
4. 肺葉切除以上の肺切除とリンパ節郭清によって腫瘍の完全切除が可能と判断されている。
5. 切除後の予測残存一秒量が800mL以上である。
※予測残存一秒量は以下の式に従って算出:
予測残存一秒量=登録前の一秒量×(18-予測される区域切除数)/18
6. Performance status(ECOG)が0~1である。
7. RECISTガイドラインversion 1.1に基づく測定可能病変を1つ以上有する。
8. 登録前14日間以内に測定された以下の臨床検査値によって、十分な臓器機能を有する。(登録日の14日前の同じ曜日の検査は許容する)
a 好中球数 ≧1,500/mm^3
b ヘモグロビン ≧ 9.0 g/dL
c 血小板数 ≧ 100,000/mm^3
d AST(SGOT) ≦ 100 IU/L (またはU/L)
e ALT(SGPT) ≦ 100 IU/L (またはU/L)
f 総ビリルビン ≦ 1.5mg/dL(ジルベール症候群の患者では総ビリルビン ≦3.0mg/dL)
g クレアチニン ≦1.5 mg / dL、又はクレアチニンクリアランス≧40 mL /分
[Cockcroft-Gault式*で40 mL / min未満であっても、24時間尿収集の測定値40 mL /分以上であれば、適格とする。]
* Cockcroft-Gault式:
男性: Ccr={(140−年齢) × 体重(kg)}/{72 × 血清CRE value (mg/dL)}
女性: Ccr=0.85 × {(140−年齢) × 体重 (kg)}/{72 × 血清CRE value (mg/dL)}
h SpO2 ≧ 92%(室内気)
i PT-INR ≦ 1.5
j PTT(aPTT) ≦ 1.5×ULN
k 尿蛋白 1+以下
(2+以上の場合は、24時間蓄尿し、24時間蛋白量が1000mg未満の場合、適格とする)
9. 妊娠する可能性のある女性被験者は、登録前7日間以内の妊娠検査(血清)で陰性である。男女ともに治験中及び治験薬最終投与から120日までの間、適切な避妊(全禁欲、子宮内避妊器具、ホルモン放出システム、又は、避妊用インプラント及び経口避妊薬)を行うことに同意している。
10. 治験参加について患者本人から文書で同意が得られている。
1. Male/female participants who are at least 20 years of age on the day of signing informed consent
2. Previously untreated and histologically proven NSCLC harboring PD-L1 expression (>=1% in a biopsy specimen), as measured by immunohistochemistry (22C3).
3. Resectable clinical stage IB-IIIA NSCLC carefully evaluated by experienced thoracic surgeons. (If N2 disease is suspected, the histological or cytological confirmation is mandatory) (UICC version 8)
4. Pulmonary resection more than lobectomy and lymph node dissection is considered to be possible for complete resection of the tumor.Be able to undergo protocol therapy, including necessary surgery.
5. Has adequate pulmonary function for pulmonary resection. Predicted postoperative FEV1.0 is 800 mL or more. {(predicted postoperative FEV1.0) = (preoperative FEV1.0) x (18-number of resected segment) / 18}
6. ECOG performance status of 0 to 1.
7. Has measurable disease as defined by RECIST 1.1 as determined by investigator.
8. Has adequate organ function as defined in the following criteria. Clinical test data must meet the following criteria within 14 days of the registration. The registration day is the standard, including the same day of the week two weeks prior.
a Neutrophil count: >= 1500/mm^3 b Hemoglobin (Hb) >= 9.0 g/dL c Platelet count: >= 10.0 x 10^4/mm^3 d AST (SGOT) <= 100 IU/L e ALT (SGPT): <= 100 IU/L f Total bilirubin: <= 1.5 mg/dL (Total bilirubin: <= 3.0 mg/dL for patient with Gilbert's syndrome) g Creatinine: CRE <= 1.5 mg/dL, or creatinine clearance of 40 mL/minute or higher [Even when the value is less than 40 mL/min in the Cockcroft-Gault equation, if the measured value from a 24-hour urine collection is 40 mL/min or higher, the patient qualifies.] * Cockcroft-Gault equation: Male: Ccr={(140 - age) x body weight (kg)} / {72 x serum CRE value (mg/dL)}Female: Ccr=0.85 x {(140 - age) x body weight (kg)} / {72 x serum CRE value (mg/dL) h SpO(2) >= 92% (room air) i International normalized ratio (INR) <= 1.5 j PTT(aPTT) <= 1.5 x ULN k Urinary protein <=1+ (if it is >=2+, store the urine for 24 hours, and if the urinary protein is <1,000 mg, the patient is qualified).
9. Female who are likely to become pregnant are negative with pregnancy tests (serum) within 7 days prior to enrollment. They agree to conduct proper contraception (total abstinence, intrauterine contraceptive device, hormone release system, or contraceptive implant and oral contraceptive) for both men and women during the trial and from the final investigational dosing up to 120 days
10. The participant (or legally acceptable representative if applicable) is willing and able to provide written informed consent/assent for the trial.
1.Has one of the following tumor locations/types:
- NSCLC involving the superior sulcus
- Large cell neuro-endocrine cancer (LCNEC)
- Sarcomatoid tumor
- Synchronous lung cancer (within 5 years), current non-pure GGN on TSCT, or pure GGN with 15mm or more on TSCT
2.Has an active infection requiring systemic therapy.
3.Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
4.Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (dose exceeding 10mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of trial drug.
5.Has a known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
6.Hypersensitivity or allergy to pembrolizumab, ramucirumab, or any of their excipients.
7.Has a known history of, or any evidence of active, interstitial lung disease.
8.Has a hypertension that is difficult to control (systolic blood pressure >=160 mmHg and diastolic blood pressure >=90 mmHg) despite treatment with several hypotensive agents.
9.Has an acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrollment
10.Has a history of New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months
11.Has a severe (hospitalization required) complications (intestinal palsy, intestinal obstruction, pulmonary fibrosis, diabetes difficult to control, heart failure, myocardial infarction, unstable angina, renal failure, liver failure, liver cirrhosis, mental disease, cerebrovascular disease etc).
12.Has a known history of human immunodeficiency virus (HIV) infection. No HIV resting is required unless mandated by local health authority.
13.Has a known history of active TB (Bacillus Tuberculosis)
14.Positive for HBs antigens, HBs antibodies, and HBc antibodies. However, if positive for HBs and/or HBc antibodies, the patient can be registered as long as they are negative for HBV-DNA.
15.Positive for HCV antibody. However, if positive for HCV antibody, the patient can be registered as long as they are negative for HCV-RNA.
16.Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
17.Has a known additional malignancy that is progressing or requires active treatment within the past (5 years) or received anti-cancer drug including hormone therapy.
Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, bladder carcinoma, or carcinoma in situ (eg, in situ cervical cancer, breast carcinoma, CIS and AIS of the lung) that have undergone potentially curative therapy are not excluded.
18.Has received a live vaccine within 30 days prior to the first dose of trial drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist) are live attenuated vaccines and are not allowed.
19.Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.
20.Has history of hemoptysis (more than 1/2 cups in teaspoon) in 2 months before registration, or invasion of major vessels by cancer or major vessel narrowing is recognized on the image.
21.Image shows cavity formation in the tumor.
22.Is considered highly likely to have complications related to bleeding.
*Obvious tumor invasion to the chest great vessel, cavity formation of the lung lesion, or the existence of obvious thrombus on the image are recognized, etc.
23.Has past history of gastrointestinal perforation, peptic ulcer, diverticulosis or fistula within 6 months.
*As for peptic ulcer, registration is permitted when disease condition is controlled by appropriate treatment.
24.Has a history of pulmonary embolism / deep vein thrombosis, or other thromboembolism within 3 months before registration.
25.Received major surgery within 28 days before registration, or received procedures for placement of subcutaneous venous access devices within seven days before registration.
26.Severe wounds, ulcers or fractures within 28 days before registration.
27.Has undergone long-term treatment using aspirin, nonsteroidal anti-inflammatory drugs (such as ibuprofen, naproxen), dipyridamole, clopidogrel or similar drugs. However, use of aspirin up to 325 mg / day once a day is acceptable.
28.Patients who are receiving anticoagulant therapy and whose dose of oral anticoagulant or low molecular weight heparin is not stable. In case of taking warfarin, registration is permitted if there is no active bleeding or no risk of bleeding.
29.Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of registration.
Note: Participants who have entered the follow-up phase of an investigational trial may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
30.Has no intention to comply with the study protocol or it is impossible to comply.
31.Investigator or clinical trial doctor judged unsuitable as subject of this trial.
investigational material(s)
Generic name etc : Pembrolizumab(Genetical Recombination)
INN of investigational material : pembrolizumab
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational material : 2 cycles of pembrolizumab 200mg intravenously every 3 weeks followed by surgical resection.
Generic name etc : Ramucirumab(Genetical Recombination)
INN of investigational material : ramucirumab
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational material : 2 cycles of ramucirumab 10mg/kg intravenously every 3 weeks followed by surgical resection.
control material(s)
Generic name etc : -
INN of investigational material : -
Therapeutic category code :
Dosage and Administration for Investigational material : -
/
/
有効性
中央判定による病理学的奏効割合
efficacy
Major pathologic response (MPR) rate by central review